

#2
10/089641

EXPRESS MAIL CERTIFICATE

101055/10101710 2 8 MAR 2012

Date 3/28/02 Label No. EV03914127305

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

DBPeeK
Name (Print)

[Signature]
Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 6181/OK439

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dae-Gun KIM; Won-Kyung CHO; Neon-Cheol JUNG; Young-Rim SEONG; Dong-Soo IM; Seung-Suh HONG; Hyun-Soo LEE

Serial No.: NOT YET ASSIGNED (U.S. NATIONAL PHASE OF PCT/KR01/01295)

Filed: CONCURRENTLY HEREWITH

For: EXPRESSION VECTOR CODING P972 GENE FOR CANCER THERAPY AND ADENOVIRUS PRODUCING THE SAME

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed: (Check one of the boxes A-D)

- ☒ [X] A. Within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
- ☐ [] B. before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
- ☐ [] C. after (A) and (B) above, but before the mailing date of a final rejection, a notice of allowance, or any other action that closes prosecution, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "ii" below.

(check one of the boxes "i" and "ii" below:)

- ☐ [] i. Counsel states that, upon information and belief, each item of information listed herein was either (a) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- ☐ [] ii. A check for the fee set forth in 1.17(p), presently believed to be \$180, is enclosed.
- ☐ [] D. after (A), (B) and (C) above, but before payment of the issue fee: Counsel states that, upon information and belief, each item of information listed herein was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS; or (ii) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- ☐ [] i. A check for the fee set forth in 1.17 (p), presently believed to be \$180, is enclosed.

2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment

hereto. A copy of each document listed is attached, except as explained below.

(check boxes A and/or B and fill in blanks, if appropriate.)

- ☐ A. Document(s) _____ is (are) deemed substantially cumulative to document(s) _____, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.
- ☐ B. Certain documents were previously cited by or submitted to the Office in the following prior applications, which are relied upon under 35 U.S.C. 120:

[SERIAL NO. & FILING DATE].

Applicant Identifies these documents by attaching hereto copies of the forms PTO- 892 and PTO- 1449 from the files of the prior application(s) or a fresh PTO- 1449 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application.

☐ 3. Document No. 1 is not in the English language. In accordance with 1.98(c), Applicant states:

- ☐ An English translation of the Abstract is enclosed.
- ☐ A concise explanation of the relevance of document(s) _____ is found in the attached search report (see MPEP § 609 A(3)x).
- ☐ A concise explanation of the relevance of document(s) _____ is set forth as follows: [Insert concise explanation of relevance]
- ☐ A concise explanation of the relevance of document(s) _____ can be found on page(s) _____ of the specification.
- ☐ A concise explanation of document(s) _____ can be found on the attached sheet.

☐ 4. No explanation of relevance is necessary for documents in the English language (see MPEP § 609 A(3)).

☒ 5. Other information being provided for the examiner's consideration follows: The undersigned is also enclosing herewith a copy of a Search Report issued December 26, 2001 for the PCT counterpart of the present patent

application (Application No. PCT/KR01/01295), in which the presently disclosed references were cited.

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless other-wise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

CROSS REFERENCE UNDER 37 C.F.R. §1.78 TO RELATED APPLICATIONS


Pursuant to 37 C.F.R. § 1.78, Applicant notes that the above-identified patent application may be related to the following U.S. Patent Applications:

(1) U.S. Patent Application Serial No _____, filed _____.

Early and favorable consideration is earnestly solicited.

March 27, 2002

Respectfully submitted,


S. Peter Ludwig
Registration No. 25,351
Attorney for Applicant(s)

DARBY & DARBY P.C.
Post Office Box 5257
New York, N.Y. 10150-5257
(212) 527-7700

10,089641

RECEIVED 28 MAR 2002
SHEET 1 OF 1**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 6181/OK439 SERIAL NO: TBA
(National Phase of PCT/KRO1/01295)
APPLICANT: Dae-Gun KIM et al. FILING DATE: HEREWITH

U.S. PATENT DOCUMENTS

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
-----------------------	--------------------	------	------	-------	----------	-------------

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
-----------------------	--------------------	------	---------	-------	----------	-----------------------

OTHER REFERENCES**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)**

*EXAMINER
INITIALS

1. "A Family of stress-Inducible GADD45-like Proteins Mediate Activation of the Stress-Responsive MTK1/MEK4 MAPKK" M. Takekawa and H. Saito, Cell, vol. 95, no. 4, pp 521-530 (November 1998).
2. "Induction of GADD45 and JNK/SAPK-Dependent Apoptosis following Inducible Expression of BRCA1" D.P. Harkin et al., Cell, vol. 97, no. 5, pp 575-586 (May 1999).
3. "A Novel Oncostatin M-inducible Gene OIG37 Forms a Gene Family with MyD118 and GADD45 and Negatively Regulates Cell Growth" K. Nakayma et al., J. Biol. Chem., vol. 274, no. 35, pp 24766-24772 (August 1999).
4. "Radiation-Induced GADD45 Expression Correlates with Clinical Response to Radiotherapy of Cervical Carcinoma" M.A. Santucci et al., Int. J. Radiation Oncology Biol. Phys., vol. 46, no. 2, pp 411-416 (January 2000).

EXAMINER: _____

DATE CONSIDERED: _____

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.